In December 1969, the first issue of the *Schizophrenia Bulletin* was issued on an experimental basis. Its appearance was followed over the next 4 years by 10 additional experimental issues. On September 25, 1974, permission was granted by the Office of Management and Budget for the *Bulletin* to be established as a regular quarterly publication. The Secretary of Health and Human Services has determined that the publication of this periodical is necessary in the transaction of the public business required by law of this Department. Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through September 30, 2003.

This is Volume 29, No. 1, 2003, of the *Schizophrenia Bulletin*, a quarterly periodical prepared by the Office of Communications and Public Liaison, National Institute of Mental Health (NIMH), National Institutes of Health. The Bulletin's purpose is to facilitate the dissemination and exchange of information about schizophrenia. Material contained in the Bulletin, including viewpoints expressed by NIMH staff members, does not necessarily reflect the opinions, official policy, or position of NIMH. All articles appearing in the Bulletin, except where otherwise noted, are in the public domain and may be reproduced or copied without requesting the author's permission.

**Contents**

Guest Editors' Introduction: What Can Large Pragmatic Clinical Trials Do for Public Mental Health Care? ........................................... 1

Jeffrey A. Lieberman and T. Scott Stroup

Approaches to Multisite Clinical Trials: The National Institute of Mental Health Perspective .................................................. 7

Barry D. Lebowitz, Benedetto Vitiello, and Grayson S. Norquist

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development ........................................ 15

T. Scott Stroup, Joseph P. McEvoy, Marvin S. Swartz, Matthew J. Byerly, Ira D. Glick, Jose M. Canive, Mark F. McGee, George M. Simpson, Michael C. Stevens, and Jeffrey A. Lieberman

Assessing Clinical and Functional Outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial .......................................................... 33

Marvin S. Swartz, Diana O. Perkins, T. Scott Stroup, Joseph P. McEvoy, Jennifer M. Nieri, and David C. Haak

Neurocognitive Assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project Schizophrenia Trial: Development, Methodology, and Rationale .................................. 45

Richard S.E. Keefe, Richard C. Mohs, Robert M. Bilder, Philip D. Harvey, Michael F. Green, Herbert Y. Meltzer, James M. Gold, and Mary Sano

Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's Disease Trial ........................................... 57

Lon S. Schneider, M. Saleem Ismail, Karen Dagerman, Sonia Davis, Jason Olin, Dennis McManus, Eric Pfeiffer, J. Michael Ryan, David L. Sultzer, and Pierre N. Tariot

Statistical Approaches to Effectiveness Measurement and Outcome-Driven Re-Randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Studies ........ 73

Sonia M. Davis, Gary G. Koch, C.E. Davis, and Lisa M. LaVange
Changing Environments and Alternative Perspectives in Evaluating the Cost-Effectiveness of New Antipsychotic Drugs

Robert Rosenheck, Jefferson Doyle, Douglas Leslie, and Alan Fontana

The Diffusion of New Antipsychotic Medications and Formulary Policy

Marisa Elena Domino, Richard G. Frank, and Robert Rosenheck

Generating Evidence to Inform Policy and Practice: The Example of the Second Generation “Atypical” Antipsychotics

John Geddes

Randomized Controlled Trials in Evidence-Based Mental Health Care: Getting the Right Answer to the Right Question

Susan M. Essock, Robert E. Drake, Richard G. Frank, and Thomas G. McGuire

Implementation of Evidence-Based Practices in State Mental Health Systems: Implications for Research and Effectiveness Studies

Vijay Ganju

Science to Services: Consumers Need “Real-World” Science

Xavier F. Amador and Michael Fitzpatrick

First Person Account: Medicines Are Not Enough

Barbara B. Smith

Psychological Trauma and Schizotypal Symptoms

Howard Berenbaum, Eve M. Valera, and John G. Kerns

The Multidimensional Scale of Independent Functioning: A New Instrument for Measuring Functional Disability in Psychiatric Populations

Judith Jaeger, Stefanie M. Bents, and Pál Czobor

Monozygotic Twins Exhibit Numerous Epigenetic Differences: Clues to Twin Discordance?

Arturus Petronis, Irving I. Gottesman, Peixiang Kan, James L. Kennedy, Vincenzo S. Basile, Andrew D. Paterson, and Violeta Popendikyte

About the Cover

The Schizophrenia Bulletin features art done by current and former mental hospital patients. The painting on the cover of this issue is by Ramell Moore, who studied abstract visual art at the University of North Carolina at Chapel Hill. The artist offers the following description of this work: “This painting shows a woman who was blinded by gases released at her workplace. It represents the danger people are exposed to working in hazardous conditions for low wages. It also conveys the onset of psychosis. The haze glazes over the eyes of disillusionment, being strangled into the depths of panicky desperation that come in the wake of this sea of disease.”